CTLA4 and melanoma: In 2011, the introduction of the first immune checkpoint inhibitor (CPI) ipilimumab, a cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) antibody, fundamentally changed cancer treatment for metastatic or unresectable melanoma (1–3).